Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity

Establishment of Frontier Exploration Laboratories (“VaxxLabs”) in Cape Canaveral, Fla., as corporate headquarters

CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla.

“Today’s announcements reflect the strength of Vaxxinity’s science and people and further equip us to achieve key research and commercial milestones as we prepare to launch our first vaccine and advance clinical development of our pipeline candidates,” said Mei Mei Hu, Chief Executive Officer of Vaxxinity. “Our new Board members bring expertise in healthcare, strategic transactions and human resources that will be invaluable for Vaxxinity going forward. Additionally, we have established Frontier Exploration Laboratories (FEL) as our corporate headquarters alongside our state-of-the art research operations facility in Cape Canaveral. This step further supports the continued growth of our pipeline and company. We are grateful for those who helped bring us to this point and look forward to working with our new team members.”

Board of Director Appointments
Vaxxinity announced the expansion of its Board of Directors with four new appointments, which include executives with expertise in life sciences, finance, M&A, high growth ventures, compliance, and public company board service. These additions bring additional balance, diversity and relevant industry experience to the Board. James Chui and Greg Blatt have resigned, resulting in a nine-director Board.

The new Board members are:

• Katherine Eade, J.D., who has more than 20 years of experience advising public companies on M&A, corporate governance and capital markets, including a dozen years serving in leadership roles in the life sciences industry. She currently serves as an independent director on the board of directors of Harvard Bioscience, Inc., since 2017, and is a member of its Audit Committee and Chair of its Governance Committee. She began her career as an attorney at Cleary Gottlieb, a leading international law firm. Katherine will join Vaxxinity’s audit committee.
  
  

• Landon Ogilvie, who has more than 25 years of experience in logistics, risk management, operations management, and organizational leadership across diverse industries. He currently serves as CEO of Co-West Inc. and Destination Systems, the largest independently owned logistics company in Colorado serving Colorado Department of Transportation, U.S. Department of Defense and many state municipalities. He began his career in the risk management sector where he was a partner with one of the oldest businesses in Texas, Gans and Smith Insurance. Landon will join Vaxxinity’s compensation committee.
  
  

• James Smith, who has more than 20 years of experience in financial and business development at various growth companies. James’ primary roles have revolved around governance, reporting, business development, sales, M&A and capital raising. He currently serves as CEO of InvitedHome and Board member of YourFare. He began his career as an auditor at Ernst & Young. James will join Vaxxinity’s audit committee.
  
  

• Gaby Toledano, who has more than 30 years of experience as a Board member, advisor and operating executive. She is currently Chief Operating Officer at Keystone Strategy and serves on the Boards of Lilium and Velo3D where she chairs the Compensation Committees of both companies. Prior to that, she served as Chief People Officer at Tesla and Executive Vice President and Chief Talent Officer at Electronic Arts and Siebel Systems. Gaby will join as Vaxxinity’s compensation committee chair and member of the nomination and governance committee.